Multidisciplinary Pain Center, Sahlgrenska University Hospital/Ostra, SE-416 85 Göteborg, Sweden.
Heart. 2010 Jul;96(14):1132-6. doi: 10.1136/hrt.2009.177188. Epub 2010 May 18.
To assess the long-term effect of spinal cord stimulation (SCS) on angina symptoms and quality of life in patients with refractory angina pectoris defined as severe angina due to coronary artery disease resistant to conventional pharmacological therapy and/or revascularisation.
During 2003-2005, all patients with refractory angina referred for SCS treatment at 10 European centres were consecutively included in the European registry for refractory angina (European Angina Registry Link, EARL), a prospective, 3-year follow-up study. In the present study, the SCS-treated patients were followed-up regarding angina symptoms and quality of life assessed was with a generic (Short Form 36, SF-36) and a disease-specific (Seattle Angina Questionnaire, SAQ) quality of life questionnaire.
In total, 235 patients were included in the study. After screening, 121 patients were implanted and followed up 12.1 months after implantation. The implanted patients reported fewer angina attacks (p<0.0001), reduced short-acting nitrate consumption (p<0.0001) and improved Canadian Cardiovascular Society class (p<0.0001). Furthermore, quality of life was significantly improved in all dimensions of the SF-36 and the SAQ. Seven (5.8%) of the implanted patients died within 1 year of follow up.
SCS treatment is associated with symptom relief and improved quality of life in patients with refractory angina pectoris suffering from severe coronary artery disease.
评估脊髓刺激(SCS)对冠状动脉疾病导致的严重心绞痛患者(即对常规药物治疗和/或血运重建有抵抗的难治性心绞痛)的心绞痛症状和生活质量的长期影响。
在 2003 年至 2005 年期间,10 个欧洲中心的所有难治性心绞痛患者在接受 SCS 治疗时连续被纳入难治性心绞痛欧洲登记处(欧洲心绞痛登记链接,EARL)的前瞻性、3 年随访研究。在本研究中,SCS 治疗的患者接受了心绞痛症状的随访,并使用通用(36 项简短健康调查,SF-36)和特定疾病(西雅图心绞痛问卷,SAQ)生活质量问卷评估生活质量。
共有 235 例患者纳入研究。筛选后,121 例患者接受了植入并在植入后 12.1 个月进行了随访。植入患者报告的心绞痛发作次数减少(p<0.0001)、短效硝酸酯类药物消耗减少(p<0.0001)和加拿大心血管学会分级改善(p<0.0001)。此外,SF-36 和 SAQ 的所有维度的生活质量均显著改善。7 例(5.8%)植入患者在随访 1 年内死亡。
SCS 治疗与缓解难治性心绞痛患者的症状和改善生活质量相关,这些患者患有严重的冠状动脉疾病。